<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age/><report-id>US-PFIZER INC-2013028715</report-id><gender>female</gender><reactions><reaction>Inflammatory breast cancer, metastates on its own and markers have gone up a little</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>Aromasin</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>AFINITOR</drug-name><manufacturer/><ingredients/></drug></drugs><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>psur</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4254113_P31</messagenumb>
		<messagesenderidentifier>PFIZERINC</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151548</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-PFIZER INC-2013028715</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-22</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-22</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-PFIZER INC-2013028715</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>PFIZERINC</senderorganization>
			<senderfamilyname>Head Drug Safety Surveillance</senderfamilyname>
			<senderstreetaddress>150 East 42nd Street</senderstreetaddress>
			<sendercity>New York</sendercity>
			<senderstate>New York</senderstate>
			<senderpostcode>10017</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2127335544</sendertel>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20785</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3019183134</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientsex code="2">Female</patientsex>
			<resultstestsprocedures>Markers (Unknown date): Have gone up a little
Genomic profile (Unknown date): 3 overamplifications, CDK4, one of her overamplifications</resultstestsprocedures>
			<reaction>
				<primarysourcereaction>Inflammatory breast cancer, metastates on its own and markers have gone up a little</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Disease progression</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Disease progression</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Inflammatory breast cancer, metastates on its own and markers have gone up a little</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Inflammatory breast cancer</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Inflammatory carcinoma of the breast</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>Aromasin</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>20-753</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform normalized="coated tablet">Coated tablet</drugdosageform>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>EXEMESTANE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Disease progression</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Disease progression</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inflammatory breast cancer</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inflammatory breast cancer</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>AFINITOR</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>EVEROLIMUS</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This is a spontaneous report from a non contactable consumer. A female patient of unspecified age and ethnicity started to receive <Semaphore x="560555" class="Medicine" value="exemestane" score="0.74" ID="251639">exemestane </Semaphore>(<Semaphore x="132847" class="Medicine" value="Aromasin" score="0.49" ID="252165">AROMASIN</Semaphore>) and <Semaphore x="558929" class="Medicine" value="everolimus" score="0.74" ID="232653">everolimus </Semaphore>(<Semaphore x="48878" class="Medicine" value="Afinitor" score="0.49" ID="287294">AFINITOR</Semaphore>) both on an unspecified date. The patient's medical history and concomitant medications were not reported. She experienced <Semaphore x="3037494" class="MedDRA LLT" value="Inflammatory carcinoma of the breast" score="1.00" ID="10021980"><Semaphore x="2055672" class="Disease or Finding" value="Inflammatory Breast Carcinoma" score="1.00" ID="C4001">inflammatory <Semaphore x="1637909" class="Disease or Finding" value="Breast Carcinoma" score="1.00" ID="C4872"><Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast </Semaphore>cancer</Semaphore></Semaphore>
     <Semaphore x="3107270" class="MedDRA LLT" value="Metastases to breast" score="1.00" ID="10027454">
      <Semaphore x="2222640" class="Disease or Finding" value="Metastatic Malignant Neoplasm to the Breast" score="1.00" ID="C7511">
       </Semaphore></Semaphore></Semaphore>
    <Semaphore x="3107270" class="MedDRA LLT" value="Metastases to breast" score="1.00" ID="10027454">
     <Semaphore x="2222640" class="Disease or Finding" value="Metastatic Malignant Neoplasm to the Breast" score="1.00" ID="C7511">
      <Semaphore x="1637909" class="Disease or Finding" value="Breast Carcinoma" score="1.00" ID="C4872">, </Semaphore><Semaphore x="3108419" class="MedDRA LLT" value="Metastasis" score="1.00" ID="10062194">metastases </Semaphore></Semaphore></Semaphore>on its own, her markers have gone up <Semaphore x="1405075" class="Disease or Finding" value="Aagenaes Syndrome" score="1.00" ID="C35709">a little </Semaphore>and she had 3 over amplifications (CDK4), one of her over amplifications. Her <Semaphore x="1972089" class="Procedure" value="Genomic Profile" score="1.00" ID="C94411">genomic profile </Semaphore>showed 3 over amplifications (CDK4 one of her over amplifications). At the time of reporting, it was unknown whether <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>with <Semaphore x="560555" class="Medicine" value="exemestane" score="0.74" ID="251639">exemestane </Semaphore>and <Semaphore x="558929" class="Medicine" value="everolimus" score="0.74" ID="232653">everolimus </Semaphore>was continuing and the <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event was also unknown.No follow up attempts possible. No further information expected.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>